Professor Iain McNeish

  • Professor of Gynaecological Oncology (Experimental Therapeutics)

telephone: 0141 330 3968
email: Iain.Mcneish@glasgow.ac.uk

Research interests

Group members:

Suzanne Dowson - Research technician and lab manager (suzanne.dowson@glasgow.ac.uk).

Darren Ennis - Translational Research Scientist (darren.ennis@glasgow.ac.uk).  Responsible for all aspects of primary tissue research in the lab, and co-ordinates the BriTROC-1 study

Elaine Leung - Clinical Research Fellow (e.leung@clinmed.gla.ac.uk).  Works on innate immune responses to oncolytic adenovirus in ovarian cancer.

Malcolm Farquharson - Clinical Research Fellow (malcolm.farquharson@glasgow.ac.uk). Working on the relationship between defective homologous recombination and platinum response in high grade serous ovarian cancer.

Josephine Walton - PhD research assistant (josephine.walton@glasgow.ac.uk).  Developing novel mouse models of high grade serous ovarian cancer.

Melanie Weigert - PhD student (m.weigert.1@glasgow.ac.uk).   Investigating the role of programmed necrosis in oncolytic adenovirus infection in ovarian cancer

Alex Binks (a.binks.1@research.gla.ac.uk). PhD student.  Working on mechanisms of cell death in oncolytic HSV infection in ovarian cancer

Pavlina Spiliopoulou - Clinical Research Fellow (pavlina.spiliopoulou@glasgow.ac.uk).  Investigating epigenetic regulation of immunogenicity in ovarian high grade serous cancer.

 

Associate members:

Laura Tookman - Clinical Research Fellow at Barts Cancer Institute, London, investigating the role of DNA damage responses in the activity of oncolytic adenovirus in ovarian cancer

Key Collaborators

James Brenton – CRUK Cambridge Institute

Fran Balkwill – Barts Cancer Institute, London

Michelle Lockley – Barts Cancer Institute, London

 

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Glasgow ECMC
    Scottish Executive Health Department
    2017 - 2018
     
  • Glasgow ECMC
    Cancer Research UK
    2017 - 2018
     
  • Cancer Research UK Clinical Trials Unit - Core Programme Funding
    Cancer Research UK
    2016 - 2017
     
  • Glasgow Cancer Centre Clinical Research Fellowship 2016/2017
    The Beatson Institute for Cancer Research
    2016 - 2017
     
  • Interleukin-6 as a therapeutic target in ovarian clear cell carcinoma
    Target Ovarian Cancer
    2016 - 2018
     
  • Improved preclinical models of high grade serous ovarian cancer
    Marsha Rivkin Center for Ovarian Cancer Research
    2016 - 2017
     
  • Developing personalised therapy for women with ovarian cancer
    Beatson Cancer Charity
    2016 - 2019
     
  • The Scottish Genomes Partnership
    Scottish Executive Health Department
    2016 - 2019
     
  • TAX-TORC2: Randomised placebo controlled trial of AZD2014 plus weekly paclitaxel in platinum resistant ovarian cancer (OCTOPUS)
    AstraZeneca UK Ltd
    2015 - 2018
     
  • Glasgow Molecular Pathology (GMP) Node
    Medical Research Council
    2015 - 2018
     
  • Evaluating cancer services across the NHS in Scotland, Wales and Northern Ireland.
    Cancer Research UK
    2015 - 2016
     
  • Hedgehog pathway inhibition and paclitaxel chemotherapy in ovarian cancer
    Cancer Research UK
    2015 - 2016
     
  • Clinical Training Award
    Cancer Research UK
    2015 - 2018
     
  • Engineering oncolytic HSV for optimal spread in epithelial ovarian tumours
    Worldwide Cancer Research
    2015 - 2017
     
  • NK cells and oncolytic virus therapy in ovarian cancer
    Wellcome Trust
    2014 - 2017
     
  • CRUKE/12/024: Nintedanib in Clear Cell Carcinoma - sample collection for translational studies
    Cancer Research UK
    2014 - 2018
     
  • The relationship between p53 mutation and inflammation in high-grade serous ovarian cancer
    Academy of Medical Sciences
    2014 - 2015
     
  • Personalised biomarkers of response in high-grade serious ovarian cancer
    Cancer Research UK
    2013 - 2016
     
  • BriTROC - The UK Ovarian Cancer Translational Collaborative
    Ovarian Cancer Action
    2013 - 2016
     

Publications

List by: Type | Date

Jump to: 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008
Number of items: 66.

2017

Kondrashova, O. et al. (2017) Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discovery, (Accepted for Publication)

Babic, A. et al. (2017) Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. Cancer Causes and Control, 28(5), pp. 459-468. (doi:10.1007/s10552-016-0841-3) (PMID:28050675)

Goranova, T. et al. (2017) Safety and utility of image-guided research biopsies in relapsed high grade serous ovarian carcinoma - experience of the BriTROC consortium. British Journal of Cancer, (doi:10.1038/bjc.2017.86) (PMID:28359078) (Early Online Publication)

Phelan, C. M. et al. (2017) Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, (doi:10.1038/ng.3826) (PMID:28346442) (Early Online Publication)

Sucheston-Campbell, L. E. et al. (2017) No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival. Cancer Epidemiology, Biomarkers and Prevention, 26(3), pp. 420-424. (doi:10.1158/1055-9965.EPI-16-0631) (PMID:27677730)

Hernandez-Fernaud, J. R. et al. (2017) Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nature Communications, 8, 14206. (doi:10.1038/ncomms14206) (PMID:28198360) (PMCID:PMC5316871)

Kar, S. P. et al. (2017) Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 116(4), pp. 524-535. (doi:10.1038/bjc.2016.426) (PMID:28103614)

Swisher, E. M. et al. (2017) Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncology, 18(1), pp. 75-87. (doi:10.1016/S1470-2045(16)30559-9) (PMID:27908594)

2016

Southey, M. C. et al. (2016) PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 53(12), pp. 800-811. (doi:10.1136/jmedgenet-2016-103839) (PMID:27595995) (PMCID:PMC5200636)

Walton, J. et al. (2016) CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high grade serous carcinoma. Cancer Research, 76(20), pp. 6118-6129. (doi:10.1158/0008-5472.CAN-16-1272) (PMID:27530326)

Lawrenson, K. et al. (2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nature Communications, 7, 12675. (doi:10.1038/ncomms12675) (PMID:27601076) (PMCID:PMC5023955)

Kar, S. P. et al. (2016) Genome-wide meta-analyses of breast, ovarian, and prostate cancer association studies identify multiple new susceptibility loci shared by at least two cancer types. Cancer Discovery, 6(9), pp. 1052-1067. (doi:10.1158/2159-8290.CD-15-1227) (PMID:27432226) (PMCID:PMC5010513)

McNeish, I. A. (2016) Prognostic pathways in early-stage ovarian cancer: can gene expression transcend histological subtype? Annals of Oncology, 27(8), pp. 1366-1368. (doi:10.1093/annonc/mdw254) (PMID:27358384)

Böhm, S. et al. (2016) Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma. Clinical Cancer Research, 22(12), pp. 3025-3036. (doi:10.1158/1078-0432.ccr-15-2657) (PMID:27306793)

Singh, N., Gilks, C. B., Hirschowitz, L., Kehoe, S., McNeish, I. A., Miller, D., Naik, R., Wilkinson, N. and McCluggage, W. G. (2016) Primary site assignment in tubo-ovarian high-grade serous carcinoma: consensus statement on unifying practice worldwide. Gynecologic Oncology, 141(2), pp. 195-198. (doi:10.1016/j.ygyno.2015.10.022) (PMID:26827965)

Piskorz, A.M. et al. (2016) Methanol-based fixation is superior to buffered formalin for next-generation sequencing of DNA from clinical cancer samples. Annals of Oncology, 27(3), pp. 532-539. (doi:10.1093/annonc/mdv613) (PMID:26681675) (PMCID:PMC4769995)

Clarke, C. J. et al. (2016) The initiator methionine tRNA drives secretion of type II collagen from stromal fibroblasts to promote tumor growth and angiogenesis. Current Biology, 26(6), pp. 755-765. (doi:10.1016/j.cub.2016.01.045) (PMID:26948875) (PMCID:PMC4819511)

Meeks, H. D. et al. (2016) BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers. Journal of the National Cancer Institute, 108(2), djv315. (doi:10.1093/jnci/djv315) (PMID:26586665) (PMCID:PMC4907358)

Tookman, L. A., Browne, A. K., Connell, C. M., Bridge, G., Ingemarsdotter, C. K., Dowson, S., Shibata, A., Lockley, M., Martin, S. and Mcneish, I. A. (2016) RAD51 and BRCA2 enhance oncolytic adenovirus Type 5 activity in ovarian cancer. Molecular Cancer Research, 14(1), pp. 44-55. (doi:10.1158/1541-7786.mcr-15-0188-t) (PMID:26452665)

Hampras, S. S. et al. (2016) Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 7(43), pp. 69097-69110. (doi:10.18632/oncotarget.10215) (PMID:27533245)

2015

Johnatty, S. E. et al. (2015) Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 21(23), pp. 5264-5276. (doi:10.1158/1078-0432.CCR-15-0632) (PMID:26152742) (PMCID:PMC4624261)

Crosbie, E.J., Edmondson, R.J., Mcneish, I.A. and Sasieni, P. (2015) Are rigid management protocols stifling innovation in cancer treatment? BJOG: An International Journal of Obstetrics and Gynaecology, 122(11), pp. 1432-1434. (doi:10.1111/1471-0528.13449) (PMID:26032865)

Kar, S. P. et al. (2015) Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention, 24(10), pp. 1574-1584. (doi:10.1158/1055-9965.epi-14-1270) (PMID:26209509)

Browne, A., Tookman, L.A., Ingemarsdotter, C.K., Bouwman, R.D., Pirlo, K., Wang, Y., Mcneish, I.A. and Lockley, M. (2015) Pharmacological inhibition of 3 integrin reduces the inflammatory toxicities caused by oncolytic adenovirus without compromising anticancer activity. Cancer Research, 75(14), pp. 2811-2821. (doi:10.1158/0008-5472.can-14-3761) (PMID:25977332)

Ingemarsdotter, C. K. et al. (2015) Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. Molecular Oncology, 9(4), pp. 791-805. (doi:10.1016/j.molonc.2014.12.007) (PMID:25560085)

Lee, A. W. et al. (2015) Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. Gynecologic Oncology, 136(3), pp. 542-548. (doi:10.1016/j.ygyno.2014.12.017) (PMID:25528498)

Chornokur, G. et al. (2015) Common genetic variation in cellular transport genes and epithelial ovarian cancer (EOC) risk. PLoS ONE, 10(6), e0128106. (doi:10.1371/journal.pone.0128106) (PMID:26091520) (PMCID:PMC4474865)

Kelemen, L.E. et al. (2015) Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 47(8), pp. 888-897. (doi:10.1038/ng.3336) (PMID:26075790)

Kuchenbaecker, K. B. et al. (2015) Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 47(2), pp. 164-171. (doi:10.1038/ng.3185)

2014

Okamoto, A. et al. (2014) Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. International Journal of Gynecological Cancer, 24(9), S20-S25. (doi:10.1097/IGC.0000000000000289)

Rockall, A. G. et al. (2014) Repeatability of quantitative FDG-PET/CT and contrast enhanced CT in recurrent ovarian carcinoma: test retest measurements for tumor FDG uptake, diameter and volume. Clinical Cancer Research, 20(10), pp. 2751-2760. (doi:10.1158/1078-0432.CCR-13-2634)

Glasspool, R.M. et al. (2014) A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. British Journal of Cancer, 110(8), pp. 1923-1929. (doi:10.1038/bjc.2014.116)

McNeish, I.A. et al. (2014) A randomised placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Annals of Oncology, 25(10), pp. 1988-1995. (doi:10.1093/annonc/mdu363)

2013

Glasspool, R.M. and McNeish, I.A. (2013) Clear cell carcinoma of ovary and uterus. Current Oncology Reports, 15(6), pp. 566-572. (doi:10.1007/s11912-013-0346-0)

Leinster, A. et al. (2013) Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer. FASEB Journal, 27(10), pp. 4244-4253. (doi:10.1096/fj.13-230441)

Hall, M., Gourley, C., Mcneish, I., Ledermann, J., Gore, M., Jayson, G., Perren, T., Rustin, G. and Kaye, S. (2013) Targeted anti-vascular therapies for ovarian cancer: current evidence. British Journal of Cancer, 108(2), pp. 250-258. (doi:10.1038/bjc.2012.541)

Whilding, L., Archibald, K., Kulbe, H., Balkwill, F., Oberg, D. and Mcneish, I. (2013) Vaccinia virus induces programmed necrosis in ovarian cancer cells. Molecular Therapy, 21(11), pp. 2074-2086. (doi:10.1038/mt.2013.195)

2012

Archibald, K.M. et al. (2012) Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium. Oncogene, 31(48), pp. 4987-4995. (doi:10.1038/onc.2011.653)

Young, A.-M. et al. (2012) Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo. Molecular Therapy, 20(9), pp. 1676-1688. (doi:10.1038/mt.2012.116)

Leinster, D.A. et al. (2012) The peritoneal tumour microenvironment of high-grade serous ovarian cancer. Journal of Pathology, 227(2), pp. 136-145. (doi:10.1002/path.4002)

Saha, A. et al. (2012) Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery. International Journal of Gynecological Cancer, 22(4), pp. 566-72. (doi:10.1097/IGC.0b013e318247727f)

Emeagi, P.U. et al. (2012) Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy. Cancer Research, 72(6), pp. 1342-1352. (doi:10.1158/0008-5472.CAN-11-2400)

Coley, H.M., Hatzimichael, E., Blagden, S., Mcneish, I., Thompson, A., Crook, T. and Syed, N. (2012) Polo like kinase 2 tumour suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer. Oncotarget, 3(1), pp. 78-83.

Stone, R.L. et al. (2012) Paraneoplastic thrombocytosis in ovarian cancer. New England Journal of Medicine, 366(7), pp. 610-618. (doi:10.1056/NEJMoa1110352)

2011

Ateh, D.D. et al. (2011) The intracellular uptake of CD95 modified paclitaxel-loaded poly(lactic-co-glycolic acid) microparticles. Biomaterials, 32(33), pp. 8538-8547. (doi:10.1016/j.biomaterials.2011.07.060)

Ledermann, J.A. et al. (2011) Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. Journal of Clinical Oncology, 29(28), pp. 3798-804. (doi:10.1200/JCO.2010.33.5208)

Vaughan, S. et al. (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer, 11(10), pp. 719-725. (doi:10.1038/nrc3144)

Coward, J. et al. (2011) Interleukin-6 as a therapeutic target in human ovarian cancer. Clinical Cancer Research, 17(18), pp. 6083-6096. (doi:10.1158/1078-0432.CCR-11-0945)

Syed, N. et al. (2011) Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Research, 71(9), pp. 3317-3327. (doi:10.1158/0008-5472.CAN-10-2048)

Ledermann, J.A. et al. (2011) Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. International Journal of Gynecological Cancer, 21(4), pp. 763-70. (doi:10.1097/IGC.0b013e31821b2669)

Connell, C.M., Shibata, A., Tookman, L.A., Archibald, K.M., Flak, M.B., Pirlo, K.J., Lockley, M., Wheatley, S.P. and McNeish, I.A. (2011) Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells. Journal of Clinical Investigation, 121(4), pp. 1283-1297. (doi:10.1172/JCI43976)

Salako, M.A., Kulbe, H., Ingemarsdotter, C.K., Pirlo, K.J., Williams, S.L., Lockley, M., Balkwill, F.R. and McNeish, I.A. (2011) Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression. Molecular Therapy, 19(3), pp. 490-499. (doi:10.1038/mt.2010.247)

2010

Trimble, E.L. et al. (2010) Current academic clinical trials in ovarian cancer: gynecologic cancer intergroup and US national cancer institute clinical trials planning meeting, May 2009. International Journal of Gynecological Cancer, 20(7), pp. 1290-1298. (doi:10.1111/IGC.0b013e3181ee1c01)

Harrington, K.J. et al. (2010) Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clinical Cancer Research, 16(15), pp. 4005-4015. (doi:10.1158/1078-0432.CCR-10-0196)

Merron, A., Baril, P., Martin-Duque, P., de la Vieja, A., Tran, L., Briat, A., Harrington, K.J., Mcneish, I.A. and Vassaux, G. (2010) Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours. European Journal of Nuclear Medicine and Molecular Imaging, 37(7), pp. 1377-1385. (doi:10.1007/s00259-009-1379-3)

Delage, B., Fennell, D.A., Nicholson, L., Mcneish, I., Lemoine, N.R., Crook, T. and Szlosarek, P.W. (2010) Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. International Journal of Cancer, 126(12), pp. 2762-72. (doi:10.1002/ijc.25202)

Coughlan, L., Alba, R., Parker, A.L., Bradshaw, A.C., Mcneish, I.A., Nicklin, S. and Baker, A. (2010) Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses, 2(10), pp. 2290-2355. (doi:10.3390/v2102290)

Elmetwali, T., Searle, P.F., Mcneish, I., Young, L.S. and Palmer, D.H. (2010) CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus. Molecular Cancer, 9(52), (doi:10.1186/1476-4598-9-52)

Flak, M.B., Connell, C.M., Chelala, C., Archibald, K., Salako, M.A., Pirlo, K.J., Lockley, M., Wheatley, S.P., Balkwill, F.R. and Mcneish, I.A. (2010) p21 promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker. Molecular Cancer, 9(175), (doi:10.1186/1476-4598-9-175)

Ingemarsdotter, C.K., Baird, S.K., Connell, C.M., Öberg, D., Halldén, G. and McNeish, I.A. (2010) Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene, 29(45), pp. 6051-6063. (doi:10.1038/onc.2010.335)

2009

Warwick, J., Vardaki, E., Fattizzi, N., Mcneish, I., Jeyarajah, A., Oram, D., Hassan, L., Covens, A., Duffy, S. and Reynolds, K. (2009) Defining the surgical management of suspected early-stage ovarian cancer by estimating patient numbers through alternative management strategies. BJOG: An International Journal of Obstetrics and Gynaecology, 116(9), pp. 1225-1241. (doi:10.1111/j.1471-0528.2009.02213.x)

Coughlan, L., Vallath, S., Saha, A., Flak, M., Mcneish, I.A., Vassaux, G., Marshall, J.F., Hart, I.R. and Thomas, G.J. (2009) In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. Journal of Virology, 83(13), pp. 6416-28. (doi:10.1128/JVI.00445-09)

Young, A.M. and Mcneish, I.A. (2009) Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time. Future Oncology, 5(3), pp. 339-357. (doi:10.2217/fon.09.11)

2008

Hagemann, T., Lawrence, T., Mcneish, I., Charles, K.A., Kulbe, H., Thompson, R.G., Robinson, S.C. and Balkwill, F.R. (2008) "Re-educating" tumor-associated macrophages by targeting NF-kappaB. Journal of Experimental Medicine, 205(6), pp. 1261-1268. (doi:10.1084/jem.20080108)

Pomel, C., Barton, D.P.J., Mcneish, I. and Shepherd, J. (2008) A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. BJOG: An International Journal of Obstetrics and Gynaecology, 115(7), pp. 808-810. (doi:10.1111/j.1471-0528.2008.01692.x)

Connell, C.M., Wheatley, S.P. and McNeish, I.A. (2008) Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysis. Cancer Research, 68(19), pp. 7923-7931. (doi:10.1158/0008-5472.CAN-08-0817)

This list was generated on Sun Jun 25 22:44:12 2017 BST.
Jump to: Articles
Number of items: 66.

Articles

Kondrashova, O. et al. (2017) Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discovery, (Accepted for Publication)

Babic, A. et al. (2017) Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. Cancer Causes and Control, 28(5), pp. 459-468. (doi:10.1007/s10552-016-0841-3) (PMID:28050675)

Goranova, T. et al. (2017) Safety and utility of image-guided research biopsies in relapsed high grade serous ovarian carcinoma - experience of the BriTROC consortium. British Journal of Cancer, (doi:10.1038/bjc.2017.86) (PMID:28359078) (Early Online Publication)

Phelan, C. M. et al. (2017) Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, (doi:10.1038/ng.3826) (PMID:28346442) (Early Online Publication)

Sucheston-Campbell, L. E. et al. (2017) No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival. Cancer Epidemiology, Biomarkers and Prevention, 26(3), pp. 420-424. (doi:10.1158/1055-9965.EPI-16-0631) (PMID:27677730)

Hernandez-Fernaud, J. R. et al. (2017) Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nature Communications, 8, 14206. (doi:10.1038/ncomms14206) (PMID:28198360) (PMCID:PMC5316871)

Kar, S. P. et al. (2017) Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 116(4), pp. 524-535. (doi:10.1038/bjc.2016.426) (PMID:28103614)

Swisher, E. M. et al. (2017) Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncology, 18(1), pp. 75-87. (doi:10.1016/S1470-2045(16)30559-9) (PMID:27908594)

Southey, M. C. et al. (2016) PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 53(12), pp. 800-811. (doi:10.1136/jmedgenet-2016-103839) (PMID:27595995) (PMCID:PMC5200636)

Walton, J. et al. (2016) CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high grade serous carcinoma. Cancer Research, 76(20), pp. 6118-6129. (doi:10.1158/0008-5472.CAN-16-1272) (PMID:27530326)

Lawrenson, K. et al. (2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nature Communications, 7, 12675. (doi:10.1038/ncomms12675) (PMID:27601076) (PMCID:PMC5023955)

Kar, S. P. et al. (2016) Genome-wide meta-analyses of breast, ovarian, and prostate cancer association studies identify multiple new susceptibility loci shared by at least two cancer types. Cancer Discovery, 6(9), pp. 1052-1067. (doi:10.1158/2159-8290.CD-15-1227) (PMID:27432226) (PMCID:PMC5010513)

McNeish, I. A. (2016) Prognostic pathways in early-stage ovarian cancer: can gene expression transcend histological subtype? Annals of Oncology, 27(8), pp. 1366-1368. (doi:10.1093/annonc/mdw254) (PMID:27358384)

Böhm, S. et al. (2016) Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma. Clinical Cancer Research, 22(12), pp. 3025-3036. (doi:10.1158/1078-0432.ccr-15-2657) (PMID:27306793)

Singh, N., Gilks, C. B., Hirschowitz, L., Kehoe, S., McNeish, I. A., Miller, D., Naik, R., Wilkinson, N. and McCluggage, W. G. (2016) Primary site assignment in tubo-ovarian high-grade serous carcinoma: consensus statement on unifying practice worldwide. Gynecologic Oncology, 141(2), pp. 195-198. (doi:10.1016/j.ygyno.2015.10.022) (PMID:26827965)

Piskorz, A.M. et al. (2016) Methanol-based fixation is superior to buffered formalin for next-generation sequencing of DNA from clinical cancer samples. Annals of Oncology, 27(3), pp. 532-539. (doi:10.1093/annonc/mdv613) (PMID:26681675) (PMCID:PMC4769995)

Clarke, C. J. et al. (2016) The initiator methionine tRNA drives secretion of type II collagen from stromal fibroblasts to promote tumor growth and angiogenesis. Current Biology, 26(6), pp. 755-765. (doi:10.1016/j.cub.2016.01.045) (PMID:26948875) (PMCID:PMC4819511)

Meeks, H. D. et al. (2016) BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers. Journal of the National Cancer Institute, 108(2), djv315. (doi:10.1093/jnci/djv315) (PMID:26586665) (PMCID:PMC4907358)

Tookman, L. A., Browne, A. K., Connell, C. M., Bridge, G., Ingemarsdotter, C. K., Dowson, S., Shibata, A., Lockley, M., Martin, S. and Mcneish, I. A. (2016) RAD51 and BRCA2 enhance oncolytic adenovirus Type 5 activity in ovarian cancer. Molecular Cancer Research, 14(1), pp. 44-55. (doi:10.1158/1541-7786.mcr-15-0188-t) (PMID:26452665)

Hampras, S. S. et al. (2016) Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 7(43), pp. 69097-69110. (doi:10.18632/oncotarget.10215) (PMID:27533245)

Johnatty, S. E. et al. (2015) Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 21(23), pp. 5264-5276. (doi:10.1158/1078-0432.CCR-15-0632) (PMID:26152742) (PMCID:PMC4624261)

Crosbie, E.J., Edmondson, R.J., Mcneish, I.A. and Sasieni, P. (2015) Are rigid management protocols stifling innovation in cancer treatment? BJOG: An International Journal of Obstetrics and Gynaecology, 122(11), pp. 1432-1434. (doi:10.1111/1471-0528.13449) (PMID:26032865)

Kar, S. P. et al. (2015) Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention, 24(10), pp. 1574-1584. (doi:10.1158/1055-9965.epi-14-1270) (PMID:26209509)

Browne, A., Tookman, L.A., Ingemarsdotter, C.K., Bouwman, R.D., Pirlo, K., Wang, Y., Mcneish, I.A. and Lockley, M. (2015) Pharmacological inhibition of 3 integrin reduces the inflammatory toxicities caused by oncolytic adenovirus without compromising anticancer activity. Cancer Research, 75(14), pp. 2811-2821. (doi:10.1158/0008-5472.can-14-3761) (PMID:25977332)

Ingemarsdotter, C. K. et al. (2015) Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. Molecular Oncology, 9(4), pp. 791-805. (doi:10.1016/j.molonc.2014.12.007) (PMID:25560085)

Lee, A. W. et al. (2015) Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. Gynecologic Oncology, 136(3), pp. 542-548. (doi:10.1016/j.ygyno.2014.12.017) (PMID:25528498)

Chornokur, G. et al. (2015) Common genetic variation in cellular transport genes and epithelial ovarian cancer (EOC) risk. PLoS ONE, 10(6), e0128106. (doi:10.1371/journal.pone.0128106) (PMID:26091520) (PMCID:PMC4474865)

Kelemen, L.E. et al. (2015) Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 47(8), pp. 888-897. (doi:10.1038/ng.3336) (PMID:26075790)

Kuchenbaecker, K. B. et al. (2015) Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 47(2), pp. 164-171. (doi:10.1038/ng.3185)

Okamoto, A. et al. (2014) Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. International Journal of Gynecological Cancer, 24(9), S20-S25. (doi:10.1097/IGC.0000000000000289)

Rockall, A. G. et al. (2014) Repeatability of quantitative FDG-PET/CT and contrast enhanced CT in recurrent ovarian carcinoma: test retest measurements for tumor FDG uptake, diameter and volume. Clinical Cancer Research, 20(10), pp. 2751-2760. (doi:10.1158/1078-0432.CCR-13-2634)

Glasspool, R.M. et al. (2014) A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. British Journal of Cancer, 110(8), pp. 1923-1929. (doi:10.1038/bjc.2014.116)

McNeish, I.A. et al. (2014) A randomised placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Annals of Oncology, 25(10), pp. 1988-1995. (doi:10.1093/annonc/mdu363)

Glasspool, R.M. and McNeish, I.A. (2013) Clear cell carcinoma of ovary and uterus. Current Oncology Reports, 15(6), pp. 566-572. (doi:10.1007/s11912-013-0346-0)

Leinster, A. et al. (2013) Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer. FASEB Journal, 27(10), pp. 4244-4253. (doi:10.1096/fj.13-230441)

Hall, M., Gourley, C., Mcneish, I., Ledermann, J., Gore, M., Jayson, G., Perren, T., Rustin, G. and Kaye, S. (2013) Targeted anti-vascular therapies for ovarian cancer: current evidence. British Journal of Cancer, 108(2), pp. 250-258. (doi:10.1038/bjc.2012.541)

Whilding, L., Archibald, K., Kulbe, H., Balkwill, F., Oberg, D. and Mcneish, I. (2013) Vaccinia virus induces programmed necrosis in ovarian cancer cells. Molecular Therapy, 21(11), pp. 2074-2086. (doi:10.1038/mt.2013.195)

Archibald, K.M. et al. (2012) Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium. Oncogene, 31(48), pp. 4987-4995. (doi:10.1038/onc.2011.653)

Young, A.-M. et al. (2012) Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo. Molecular Therapy, 20(9), pp. 1676-1688. (doi:10.1038/mt.2012.116)

Leinster, D.A. et al. (2012) The peritoneal tumour microenvironment of high-grade serous ovarian cancer. Journal of Pathology, 227(2), pp. 136-145. (doi:10.1002/path.4002)

Saha, A. et al. (2012) Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery. International Journal of Gynecological Cancer, 22(4), pp. 566-72. (doi:10.1097/IGC.0b013e318247727f)

Emeagi, P.U. et al. (2012) Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy. Cancer Research, 72(6), pp. 1342-1352. (doi:10.1158/0008-5472.CAN-11-2400)

Coley, H.M., Hatzimichael, E., Blagden, S., Mcneish, I., Thompson, A., Crook, T. and Syed, N. (2012) Polo like kinase 2 tumour suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer. Oncotarget, 3(1), pp. 78-83.

Stone, R.L. et al. (2012) Paraneoplastic thrombocytosis in ovarian cancer. New England Journal of Medicine, 366(7), pp. 610-618. (doi:10.1056/NEJMoa1110352)

Ateh, D.D. et al. (2011) The intracellular uptake of CD95 modified paclitaxel-loaded poly(lactic-co-glycolic acid) microparticles. Biomaterials, 32(33), pp. 8538-8547. (doi:10.1016/j.biomaterials.2011.07.060)

Ledermann, J.A. et al. (2011) Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. Journal of Clinical Oncology, 29(28), pp. 3798-804. (doi:10.1200/JCO.2010.33.5208)

Vaughan, S. et al. (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer, 11(10), pp. 719-725. (doi:10.1038/nrc3144)

Coward, J. et al. (2011) Interleukin-6 as a therapeutic target in human ovarian cancer. Clinical Cancer Research, 17(18), pp. 6083-6096. (doi:10.1158/1078-0432.CCR-11-0945)

Syed, N. et al. (2011) Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Research, 71(9), pp. 3317-3327. (doi:10.1158/0008-5472.CAN-10-2048)

Ledermann, J.A. et al. (2011) Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. International Journal of Gynecological Cancer, 21(4), pp. 763-70. (doi:10.1097/IGC.0b013e31821b2669)

Connell, C.M., Shibata, A., Tookman, L.A., Archibald, K.M., Flak, M.B., Pirlo, K.J., Lockley, M., Wheatley, S.P. and McNeish, I.A. (2011) Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells. Journal of Clinical Investigation, 121(4), pp. 1283-1297. (doi:10.1172/JCI43976)

Salako, M.A., Kulbe, H., Ingemarsdotter, C.K., Pirlo, K.J., Williams, S.L., Lockley, M., Balkwill, F.R. and McNeish, I.A. (2011) Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression. Molecular Therapy, 19(3), pp. 490-499. (doi:10.1038/mt.2010.247)

Trimble, E.L. et al. (2010) Current academic clinical trials in ovarian cancer: gynecologic cancer intergroup and US national cancer institute clinical trials planning meeting, May 2009. International Journal of Gynecological Cancer, 20(7), pp. 1290-1298. (doi:10.1111/IGC.0b013e3181ee1c01)

Harrington, K.J. et al. (2010) Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clinical Cancer Research, 16(15), pp. 4005-4015. (doi:10.1158/1078-0432.CCR-10-0196)

Merron, A., Baril, P., Martin-Duque, P., de la Vieja, A., Tran, L., Briat, A., Harrington, K.J., Mcneish, I.A. and Vassaux, G. (2010) Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours. European Journal of Nuclear Medicine and Molecular Imaging, 37(7), pp. 1377-1385. (doi:10.1007/s00259-009-1379-3)

Delage, B., Fennell, D.A., Nicholson, L., Mcneish, I., Lemoine, N.R., Crook, T. and Szlosarek, P.W. (2010) Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. International Journal of Cancer, 126(12), pp. 2762-72. (doi:10.1002/ijc.25202)

Coughlan, L., Alba, R., Parker, A.L., Bradshaw, A.C., Mcneish, I.A., Nicklin, S. and Baker, A. (2010) Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses, 2(10), pp. 2290-2355. (doi:10.3390/v2102290)

Elmetwali, T., Searle, P.F., Mcneish, I., Young, L.S. and Palmer, D.H. (2010) CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus. Molecular Cancer, 9(52), (doi:10.1186/1476-4598-9-52)

Flak, M.B., Connell, C.M., Chelala, C., Archibald, K., Salako, M.A., Pirlo, K.J., Lockley, M., Wheatley, S.P., Balkwill, F.R. and Mcneish, I.A. (2010) p21 promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker. Molecular Cancer, 9(175), (doi:10.1186/1476-4598-9-175)

Ingemarsdotter, C.K., Baird, S.K., Connell, C.M., Öberg, D., Halldén, G. and McNeish, I.A. (2010) Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene, 29(45), pp. 6051-6063. (doi:10.1038/onc.2010.335)

Warwick, J., Vardaki, E., Fattizzi, N., Mcneish, I., Jeyarajah, A., Oram, D., Hassan, L., Covens, A., Duffy, S. and Reynolds, K. (2009) Defining the surgical management of suspected early-stage ovarian cancer by estimating patient numbers through alternative management strategies. BJOG: An International Journal of Obstetrics and Gynaecology, 116(9), pp. 1225-1241. (doi:10.1111/j.1471-0528.2009.02213.x)

Coughlan, L., Vallath, S., Saha, A., Flak, M., Mcneish, I.A., Vassaux, G., Marshall, J.F., Hart, I.R. and Thomas, G.J. (2009) In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. Journal of Virology, 83(13), pp. 6416-28. (doi:10.1128/JVI.00445-09)

Young, A.M. and Mcneish, I.A. (2009) Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time. Future Oncology, 5(3), pp. 339-357. (doi:10.2217/fon.09.11)

Hagemann, T., Lawrence, T., Mcneish, I., Charles, K.A., Kulbe, H., Thompson, R.G., Robinson, S.C. and Balkwill, F.R. (2008) "Re-educating" tumor-associated macrophages by targeting NF-kappaB. Journal of Experimental Medicine, 205(6), pp. 1261-1268. (doi:10.1084/jem.20080108)

Pomel, C., Barton, D.P.J., Mcneish, I. and Shepherd, J. (2008) A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. BJOG: An International Journal of Obstetrics and Gynaecology, 115(7), pp. 808-810. (doi:10.1111/j.1471-0528.2008.01692.x)

Connell, C.M., Wheatley, S.P. and McNeish, I.A. (2008) Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysis. Cancer Research, 68(19), pp. 7923-7931. (doi:10.1158/0008-5472.CAN-08-0817)

This list was generated on Sun Jun 25 22:44:12 2017 BST.